5A6-18543-66068
4 vaccinations
4 coded responses
23 check-ins
4 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 024 / MA
- Registered
- 2021-01-22
- Relationship
- Self
- Race
- N/A
- Ethnicity
- N/A
Timeline
-
2021-01-22
Registered in v-safe
-
2021-01-22
Dose 1 — Pfizer-BioNTech
- 2021-01-23
- 2021-01-24
- 2021-01-25
- 2021-01-26
- 2021-01-27
- 2021-01-28
- 2021-01-29
- 2021-02-05
-
2021-02-11
Dose 2 — Pfizer-BioNTech
-
2021-02-13
Survey response — days 1–6 daily, dose 2MedDRA: Emotional disorder — Feeling: Fair · Site: Pain · Fever · Joint pains, Muscle or body aches, Fatigue or tiredness, Nausea · Be unable to do your normal daily activitiesFree text: Emotional sensitivityMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-02-14
Survey response — days 1–6 daily, dose 2MedDRA: Emotional disorder, Hunger — Feeling: Fair · Fever · Chills, Muscle or body aches, Fatigue or tiredness, Nausea, Abdominal pain · Be unable to do your normal daily activitiesFree text: Emotionally sensitive, hungryMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-02-16
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Fever · Chills, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
- 2021-02-17
- 2021-02-18
- 2021-02-25
- 2021-03-04
- 2021-03-11
- 2021-03-18
- 2021-03-25
- 2021-05-13
- 2021-08-12
-
2021-12-27
Dose 3 — Pfizer-BioNTech
-
2022-02-11
Survey response — 12 months, dose 2MedDRA: Pregnancy — Feeling: Good · Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, Outpatient clinic or urgent care clinic visitFree text: PregnancyMedDRA releases: 2024-11 · check-in free text available
-
2022-02-11
Report sent to call center — 12 months, dose 2Get care from a doctor or other healthcare professionalTelehealth, virtual health, or email health consultation · Outpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-02-16
-
2022-06-27
Survey response — 6 months, dose 3MedDRA: Anosmia, COVID-19, Chills, Dyspnoea, Fatigue, Malaise, Pregnancy, Productive cough — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Contracted covid-19 around May 3, 3rd trimester. Shortness of breath, chills, fatigue, malaise, phlegm, loss of smellMedDRA releases: 2024-11 · check-in free text available
-
2022-11-17
Dose 4 — Pfizer-BioNTech
- 2023-05-20
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-22 | Pfizer-BioNTech | |
| 2 | 2021-02-11 | Pfizer-BioNTech | |
| 3 | 2021-12-27 | Pfizer-BioNTech | No |
| 4 | 2022-11-17 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-02-11 | Unsuccessful |
Free text
Release 4 — days 1–6 daily, dose 2
Systemic reaction (other): Emotional sensitivity
Systemic reaction (other): Emotionally sensitive, hungry
Release 11 — 12 months, dose 2
Symptoms: Pregnancy
Release 12 — 6 months, dose 3
Symptoms: Contracted covid-19 around May 3, 3rd trimester. Shortness of breath, chills, fatigue, malaise, phlegm, loss of smell
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Anosmia | · | · | ✓ |
| SD | Chills | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Dyspnoea | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Malaise | · | · | ✓ |
| SD | Pregnancy | · | · | ✓ |
| SD | Productive cough | · | · | ✓ |
| SRO | Emotional disorder | ✓ | ✓ | ✓ |
| SRO | Hunger | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release